EyePoint, Inc. (EYPT) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Eyepoint, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.596 Good morning. My name is Michelle and I will be your conference operator today. 00:00:03.596 -- 00:00:07.721 At this time, I would like to welcome everyone to the iPoint fourth quarter and full 00:00:07.721 -- 00:00:13.268 year 2024 financial results and recent corporate development conference call. 00:00:13.268 -- 00:00:17.914 There will be a question and answer session to follow the completion of the prepared 00:00:17.914 -- 00:00:22.620 remarks. Please be advised that this call is being recorded at the company's request. 00:00:22.620 -- 00:00:26.925 I would now like to turn the call over to George Elston, Executive Vice President and 00:00:26.925 -- 00:00:31.589 Financial Officer of iPoint. Please go ahead, sir. 00:00:32.077 -- 00:00:36.341 Thank you, and thank you all for joining us on today's conference call to discuss IPoint's 00:00:36.341 -- 00:00:42.307 fourth quarter and full year 2024 financial results and recent corporate developments. 00:00:42.307 -- 00:00:46.991 With me today is Dr. Jay Duker, President and Chief Executive Officer. 00:00:46.991 -- 00:00:51.135 Jay will begin with a review of recent corporate updates and discuss the ongoing clinical 00:00:51.135 -- 00:00:55.759 trials for DuraView. I will close with commentary on the fourth quarter and full year 00:00:55.759 -- 00:01:00.713 2024 financial results, and we will then open the call for your questions. 00:01:00.713 -- 00:01:04.977 Earlier this morning, we issued a press release detailing our financial results and recent 00:01:04.977 -- 00:01:09.141 corporate developments. A copy of the release can be found in the Investor Relations 00:01:09.141 -- 00:01:13.444 tab on the company website, www.ipointpharma.com. 00:01:15.688 -- 00:01:19.552 Before we begin our ...